Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Account Payables

Amounts the company owes suppliers for goods and services received.

Cerus CorporationNASDAQ: CERS

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 14.9% from a year ago

Account payables stood at $31.79M at the end of Q1 FY2026, up 14.9% from a year earlier and up 13.5% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.

Context

  • Account payables amounted to 14.3% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +14.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.79M+13.5% QoQ
Last fiscal yearDec 2025
$28.01M+29.1% YoY
Year agoMar 2025
$27.68M+14.9% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.9%——
1 year+29.1%——
3-year CAGR-5.3%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
28.01M USD
Year-over-year change
+29.1%
4-year CAGR
-5.8%

Account Payables vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +14.9% is the 2nd highest of 4, against a peer median of +13.9%.
  • Account payables amounts to 14.3% of total assets for CERS, versus a peer median of 4.6%.
CERS Competitors
Account Payables for CERS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GRFSGrifols, S.A.Jun 2026€1B EUR+13.9%+2.2%5.0%
HAEHaemonetics CorporationJun 2026$56.34M USD+22.4%-7.2%2.4%
CERSCerus CorporationMar 2026$31.79M USD+14.9%-5.3%14.3%
ADMAADMA Biologics, Inc.Jun 2026$31.72M USD+6.6%+19.4%4.6%
Peer median (excluding CERS) —+13.9%+2.2%4.6%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents48.76M35.59M11.65M20.27M19.96M
Short-term Investments80.6M66.57M54.21M60.19M62.92M
Net Receivables25.13M34.43M35.5M29.78M30.37M
Inventory26.79M29M39.87M38.15M56.1M
Other Current Assets04.56M3.22M3.64M5.03M
Total Current Assets187.1M170.14M144.44M152.02M174.38M
Property, Plant & Equipment (Net)25.18M23.48M19.35M15.54M19.33M
Goodwill1.32M1.32M1.32M1.32M1.32M
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets23.9M23.15M32.64M32.04M26.83M
Total Non-current Assets50.4M47.95M53.31M48.9M47.48M
Total Assets237.5M218.09M197.75M200.92M221.86M
Account Payables35.61M33M23.84M21.7M28.01M
Short-term Debt14.7M56.16M20M19.3M43.34M
Tax Payables00000
Deferred Revenue673K589K2M1.4M1.27M
Other Current Liabilities18.51M17.58M11.82M11.94M18.26M
Total Current Liabilities78.56M117.06M67.52M63.61M100.8M
Long-term Debt54.72M13.64M59.8M64.86M40.55M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.34M3.5M3.24M3.89M5.4M
Total Non-current Liabilities73.33M32.47M76.78M80.41M56.09M
Total Liabilities151.88M149.53M144.3M144.02M156.89M
Common Stock174K177K181K186K192K
Retained Earnings(964.34M)(1.01B)(1.04B)(1.07B)(1.08B)
Accumulated OCI(149K)(2.79M)(1.27M)(400K)(156K)
Other Stockholders Equity00000
Minority Interest998K952K794K751K741K
Total Equity85.62M68.56M53.44M56.9M64.97M
Total Debt87.59M87.24M96M98.1M96.95M
Net Debt38.83M51.65M84.35M77.83M76.99M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.